Skip to contentA
Adaptimmune Therapeutics PLC
A
ADAPYAdaptimmune Therapeutics PLC Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$11.03M$11.03Mderived+678.3% vs Q4 2021 Net Income-$29.25M-$29.25MderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$27,242,000N/M Operating Cash Flowderived$2,042,000−98.5% Free Cash Flowderived-$1,373,000N/M Margins · derivedOperating margin-247.0%+2778.0 pt vs Q4 2021
Net margin-265.2%+2477.0 pt vs Q4 2021
ended Dec 31, 2022 · filed Mar 6, 2023 · 65 d after period end